Zobrazeno 1 - 10
of 52
pro vyhledávání: '"R. Daniel Benz"'
Autor:
Emiel Rorije, David Kirkland, Jennifer Y. Tanir, Kerry L. Dearfield, Mirjam Luijten, Albert P. Li, Rosalie K. Elespuru, Errol Zeiger, Carole L. Yauk, Véronique Thybaud, Lynn H. Pottenger, Francesco Marchetti, George R. Douglas, Jeffrey C. Bemis, Jan van Benthem, George E. Johnson, B. Bhaskar Gollapudi, Matthew J. LeBaron, R. Daniel Benz
Publikováno v:
Environmental and Molecular Mutagenesis. 58:264-283
For several decades, regulatory testing schemes for genetic damage have been standardized where the tests being utilized examined mutations and structural and numerical chromosomal damage. This has served the genetic toxicity community well when most
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb5cf56638116f5fb2ffc151b7c967e5
https://doi.org/10.1002/em.22045
https://doi.org/10.1002/em.22045
Autor:
Kerry L, Dearfield, B Bhaskar, Gollapudi, Jeffrey C, Bemis, R Daniel, Benz, George R, Douglas, Rosalie K, Elespuru, George E, Johnson, David J, Kirkland, Matthew J, LeBaron, Albert P, Li, Francesco, Marchetti, Lynn H, Pottenger, Emiel, Rorije, Jennifer Y, Tanir, Veronique, Thybaud, Jan, van Benthem, Carole L, Yauk, Errol, Zeiger, Mirjam, Luijten
Publikováno v:
Environmental and molecular mutagenesis. 58(5)
For several decades, regulatory testing schemes for genetic damage have been standardized where the tests being utilized examined mutations and structural and numerical chromosomal damage. This has served the genetic toxicity community well when most
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::30ac4f4be15593d74b847a31cf721196
https://pubmed.ncbi.nlm.nih.gov/27650663
https://pubmed.ncbi.nlm.nih.gov/27650663
Autor:
Ann M. Richard, Ronald D. Snyder, Michael D. Waters, Brinda Mahadevan, Raymond A. Kemper, R. Daniel Benz, Raymond R. Tice
Publikováno v:
Environmental and Molecular Mutagenesis. 52:339-354
A symposium at the 40th anniversary of the Environmental Mutagen Society, held from October 24–28, 2009 in St. Louis, MO, surveyed the current status and future directions of genetic toxicology. This article summarizes the presentations and provide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c822d337d505792a97fe9cebdbfdee31
https://doi.org/10.1002/em.20653
https://doi.org/10.1002/em.20653
Autor:
Jan van Benthem, David Jacobson-Kram, Véronique Thybaud, Masamitsu Honma, Rosalie K. Elespuru, Richard M. Walmsley, Jiri Aubrecht, Russell T. Naven, Stephen D. Dertinger, Paul D. White, George R. Douglas, Jennifer C. Sasaki, Marilyn J. Aardema, R. Daniel Benz, Albert J. Fornace, Marlies De Boeck, Patricia A. Escobar, Anthony M. Lynch, Eiji Yamamura, Robert H. Schiestl, James H. Kim, James F. Rusling
Publikováno v:
Environmental and Molecular Mutagenesis. 52:205-223
The International Life Sciences Institute (ILSI) Health and Environmental Sciences Institute (HESI) Project Committee on the Relevance and Follow-up of Positive Results in In Vitro Genetic Toxicity (IVGT) Testing established an Emerging Technologies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47b881580e5ed072abe6e0faea67f8c4
https://doi.org/10.1002/em.20614
https://doi.org/10.1002/em.20614
Autor:
Naomi L. Kruhlak, Edwin J. Matthews, Joseph F. Contrera, Carling Ursem, Philip M. MacLaughlin, R. Daniel Benz
Publikováno v:
Regulatory Toxicology and Pharmacology. 54:1-22
The Informatics and Computational Safety Analysis Staff at the US FDA’s Center for Drug Evaluation and Research has created a database of pharmaceutical adverse effects (AEs) linked to pharmaceutical chemical structures and estimated population exp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb5d56a3f990770a8abc2481a5ae0508
https://doi.org/10.1016/j.yrtph.2008.12.009
https://doi.org/10.1016/j.yrtph.2008.12.009
Publikováno v:
Regulatory Toxicology and Pharmacology. 47:115-135
A weight of evidence (WOE) reproductive and developmental toxicology (reprotox) database was constructed that is suitable for quantitative structure-activity relationship (QSAR) modeling and human hazard identification of untested chemicals. The data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e781af5f3de554cdfc5e252e36514dff
https://doi.org/10.1016/j.yrtph.2006.11.002
https://doi.org/10.1016/j.yrtph.2006.11.002
Autor:
Gilles Klopman, Naomi Kruhlak, Julian M. Ivanov, Edwin J. Matthews, Joseph F. Contrera, R. Daniel Benz
Publikováno v:
Regulatory Toxicology and Pharmacology. 47:136-155
This report describes the construction, optimization and validation of a battery of quantitative structure-activity relationship (QSAR) models to predict reproductive and developmental (reprotox) hazards of untested chemicals. These models run with M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::043239b2da1c6fc6b4378ec5f7b6778c
https://doi.org/10.1016/j.yrtph.2006.10.001
https://doi.org/10.1016/j.yrtph.2006.10.001
Autor:
R. Daniel Benz
Publikováno v:
Expert Opinion on Drug Metabolism & Toxicology. 3:109-124
In this article the author attempts to introduce those not familiar with computational toxicology to some of the terminology and basic principles of the field. The author then reports on the progress that the FDA, Center for Drug Evaluation and Resea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::981be801df88868ec7482355e512c43d
https://doi.org/10.1517/17425255.3.1.109
https://doi.org/10.1517/17425255.3.1.109
Publikováno v:
Regulatory Toxicology and Pharmacology. 44:97-110
This study examined a novel method to identify carcinogens that employed expanded data sets composed of in silico data pooled with actual experimental genetic toxicity (genetox) and reproductive and developmental toxicity (reprotox) data. We construc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1ab84da4e2c7a102b018d3790396da8
https://doi.org/10.1016/j.yrtph.2005.10.004
https://doi.org/10.1016/j.yrtph.2005.10.004
Publikováno v:
Regulatory Toxicology and Pharmacology. 40:185-206
Estimating the maximum recommended starting dose (MRSD) of a pharmaceutical for phase I human clinical trials and the no observed effect level (NOEL) for non-pharmaceuticals is currently based exclusively on an extrapolation of the results of animal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dbabfc3c550dc05246d4b15f4fcedf6
https://doi.org/10.1016/j.yrtph.2004.08.004
https://doi.org/10.1016/j.yrtph.2004.08.004